Search

Displaying results 2201 - 2210 of 10000 in total
  1. Drug

    Dinalbuphine sebacate

    go.drugbank.com/drugs/DB15341
    Investigational

    Dinalbuphine sebacate is under investigation in clinical trial NCT02468128 (A Study of Intramuscular Sebacoyl Dinalbuphine Ester for Post-Hemorrhoidectomy Pain Management).

    Products: NALDEBAIN® EXTENDED RELEASE INJECTION 75MG/ML
  2. Drug

    Cerivastatin

    go.drugbank.com/drugs/DB00439
    ApprovedWithdrawn

    Food and Drug Administration (FDA) announced that Bayer Pharmaceutical Division voluntarily withdrew Baycol from the U.S. market, due to reports of fatal rhabdomyolysis, a severe adverse reaction from

    Categories: Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 Substrates
  3. Drug

    Toloxatone

    go.drugbank.com/drugs/DB09245
    Experimental

    Toloxatone is an antidepressant agent, the first ever use of which was in France, 1984. It acts as a selective and reversible inhibitor of monoamine oxidase-A (MOA) [L1388].

    Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates, Monoamine Oxidase A Inhibitors
  4. Drug

    AC-100

    go.drugbank.com/drugs/DB05671
    Investigational

    AC-100 is a novel synthetic peptide derived from an endogenous human protein produced by bone and dental cells (a fragment from matrix extracellular phosphoglycoprotein).

  5. Drug

    Fruquintinib

    go.drugbank.com/drugs/DB11679
    ApprovedInvestigational

    The first approach can be exemplified by [bevacizumab], a VEGF-A trap antibody. … Therefore, the advent of fruquintinib, a new generation of VEGFR inhibitors with a high kinome selectivity, demonstrated the feasibility of the small-molecule inhibitor approach.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 Substrates
  6. Drug

    Velpatasvir

    go.drugbank.com/drugs/DB11613
    ApprovedInvestigational

    Velpatasvir acts as a defective substrate for NS5A (Non-Structural Protein 5A), a non-enzymatic viral protein that plays a key role in Hepatitis C Virus replication, assembly, and modulation of host immune … a high barrier to resistance [L852].

    Mixtures: VOSEVİ 400 MG/ 100 MG/ 100 MG FİLM KAPLI TABLET, 28 ADETCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  7. Drug

    Aprocitentan

    go.drugbank.com/drugs/DB15059
    ApprovedInvestigational

    Approximately 10-15% of patients with hypertension have resistant hypertension, defined as uncontrolled high blood pressure despite the combined use of a renin-angiotensin system blocker, a calcium channel … blocker, and a diuretic at maximally tolerated doses.

    Categories: Cytochrome P-450 CYP2C18 Inhibitors, Cytochrome P-450 CYP3A Inducers
  8. Drug

    Florfenicol

    go.drugbank.com/drugs/DB11413
    ExperimentalVet approved

    Florfenicol is a fluorinated synthetic analog of thiamphenicol.

    Products: Florcol Oral Solution 250mg/ml
  9. Drug

    Bemotrizinol

    go.drugbank.com/drugs/DB11206
    Approved

    It primarily absorbs UV-A rays.

    Mixtures: Fascy Lab Green Plus Sun, Nourishing Day Cream CRème De Jour Nourrissante SPF 15 Fps 15
  10. Drug

    NOX-100

    go.drugbank.com/drugs/DB05799
    Investigational

    NOX-100 is the first in a series of proprietary NO neutralizing compounds Medinox is developing to bind and inactivate NO, a simple gas molecule that is a key biological messenger in the body. … NOX-100 is the new nitric oxide (NO) neutralizing agent being developed by San Diego-based Medinox -- demonstrated its effectiveness and potential as a therapeutic to treat hemorrhagic shock.